CN110759908B - 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 - Google Patents

用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 Download PDF

Info

Publication number
CN110759908B
CN110759908B CN201911104054.1A CN201911104054A CN110759908B CN 110759908 B CN110759908 B CN 110759908B CN 201911104054 A CN201911104054 A CN 201911104054A CN 110759908 B CN110759908 B CN 110759908B
Authority
CN
China
Prior art keywords
compound
deuterium
cancer
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911104054.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110759908A (zh
Inventor
王义汉
刘志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Tajirui Biopharmaceutical Co ltd
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Publication of CN110759908A publication Critical patent/CN110759908A/zh
Application granted granted Critical
Publication of CN110759908B publication Critical patent/CN110759908B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201911104054.1A 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 Active CN110759908B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710493544X 2017-06-26
CN201710493544 2017-06-26
CN201810661179.3A CN108658983B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201810661179.3A Division CN108658983B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Publications (2)

Publication Number Publication Date
CN110759908A CN110759908A (zh) 2020-02-07
CN110759908B true CN110759908B (zh) 2021-03-12

Family

ID=63772870

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911104054.1A Active CN110759908B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
CN201810661179.3A Active CN108658983B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810661179.3A Active CN108658983B (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Country Status (6)

Country Link
US (1) US11718611B2 (enExample)
EP (1) EP3626241B1 (enExample)
JP (2) JP7374496B2 (enExample)
CN (2) CN110759908B (enExample)
ES (1) ES3028360T3 (enExample)
WO (1) WO2019001383A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
CN115697967B (zh) * 2020-07-10 2024-10-22 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
US20240408085A1 (en) * 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN115286689B (zh) * 2022-09-29 2023-01-06 上海睿跃生物科技有限公司 靶向降解Bcl-2蛋白的化合物及其应用和药物
CN115872963A (zh) * 2022-12-27 2023-03-31 南京哈柏医药科技有限公司 一种维奈托克中间体的合成方法
CN118373787A (zh) * 2024-04-26 2024-07-23 苏州九鹭生物医药有限公司 一种氘代n-酰基磺酰胺类化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328474A (zh) * 2010-11-23 2013-09-25 Abbvie公司 细胞凋亡诱导剂的盐和晶形
CN103402521A (zh) * 2010-11-23 2013-11-20 Abbvie公司 使用选择性的bcl-2抑制剂的治疗方法
CN103987711A (zh) * 2011-10-14 2014-08-13 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3481397A1 (en) * 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328474A (zh) * 2010-11-23 2013-09-25 Abbvie公司 细胞凋亡诱导剂的盐和晶形
CN103402521A (zh) * 2010-11-23 2013-11-20 Abbvie公司 使用选择性的bcl-2抑制剂的治疗方法
CN103987711A (zh) * 2011-10-14 2014-08-13 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2019111040541;王瑞;《STN registry数据库》;20101219;全文 *
Pubchem Compound for CID 91971911;None;《U.S. National library of Medicine》;20151102;第1-2页中3D结构和IUPAC名称 *
氘代作用在药物研究中的应用;江文峰等;《齐鲁药事》;20101231;第29卷(第11期);第682-683页 *

Also Published As

Publication number Publication date
US20200216442A1 (en) 2020-07-09
ES3028360T3 (en) 2025-06-19
US11718611B2 (en) 2023-08-08
EP3626241A1 (en) 2020-03-25
EP3626241A4 (en) 2020-05-27
CN110759908A (zh) 2020-02-07
CN108658983B (zh) 2019-12-20
JP2022071077A (ja) 2022-05-13
EP3626241B1 (en) 2025-04-23
CN108658983A (zh) 2018-10-16
JP7374496B2 (ja) 2023-11-07
WO2019001383A1 (zh) 2019-01-03
JP2020527166A (ja) 2020-09-03

Similar Documents

Publication Publication Date Title
CN108658983B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
CN108623576B (zh) 用于抑制激酶活性的吲唑类化合物及其组合物及应用
IL282737B1 (en) Cyclin-dependent kinase 7 (CDK7) inhibitors
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
JP2024050645A (ja) ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
CN107686477A (zh) 作为cdk4/6抑制剂的新型化合物及其应用
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
RU2761825C1 (ru) Соединения дейтерированного дефактиниба и их применение
CN111718332B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN110066272B (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
WO2017148290A1 (zh) 一种取代的腺嘌呤化合物及其药物组合物
CN117624161A (zh) 一种吡啶羧酸胺衍生物及其应用
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
US20190062307A1 (en) Deuterium-substituted quinoline derivatives
WO2024008083A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
HK40061853B (en) Compound useful as cdk7 kinase inhibitor and use thereof
HK40090211B (en) Compound used as ret kinase inhibitor and application thereof
CN114341137A (zh) 二氢嘧啶衍生物及其用途
HK40046113A (en) Heteroaryl-substituted pyrazole compound and medicinal use thereof
WO2025086243A1 (zh) 白细胞受体酪氨酸激酶抑制剂
TW201512203A (zh) 埃克替尼馬來酸鹽的晶型及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 518057 Guangdong Province, Shenzhen City, Nanshan District, Yehai Street, Keyuan Road 15, KeXing Science Park A Building, Unit 301, Unit 1

Patentee after: Shenzhen Tajirui Biopharmaceutical Co.,Ltd.

Country or region after: China

Address before: 518057 Guangdong Province, Shenzhen City, Nanshan District, Yehai Street, Keyuan Road 15, KeXing Science Park A Building, Unit 301, Unit 1

Patentee before: SHENZHEN TARGETRX, Inc.

Country or region before: China